33 min listen
Episode 235: Danny Heng and the IMDC classification in renal cancer
FromThe Uromigos
ratings:
Length:
28 minutes
Released:
Apr 24, 2023
Format:
Podcast episode
Description
Daniel Heng, MD, MPH, FRCPC, joins us to discuss IMDC
classification for renal cell carcinoma and the treatment of patients with
favorable risk disease. Dr. Heng is a professor of oncology at the University
of Calgary in Alberta, Canada, and is the leader of the International mRCC
Database Consortium (IMDC) which consists of data from over 9,200 patients with
mRCC treated with targeted therapies from over 38 cancer centers worldwide.
classification for renal cell carcinoma and the treatment of patients with
favorable risk disease. Dr. Heng is a professor of oncology at the University
of Calgary in Alberta, Canada, and is the leader of the International mRCC
Database Consortium (IMDC) which consists of data from over 9,200 patients with
mRCC treated with targeted therapies from over 38 cancer centers worldwide.
Released:
Apr 24, 2023
Format:
Podcast episode
Titles in the series (100)
Episode 3: Pembrolizumab in Non-Muscle Invasive Bladder Cancer by The Uromigos